Psychiatric nurse practitioners can prescribe ADHD medications, including Schedule II stimulants such as Adderall, Vyvanse and Ritalin, in most states — provided they hold the appropriate DEA registration and meet their state's practice requirements. The clinical training is the same whether the prescriber is a psychiatrist or a psychiatric-mental health nurse practitioner, but state law determines whether a PMHNP can prescribe independently or must work under physician supervision, and a small number of states prohibit nurse practitioners from prescribing Schedule II controlled substances altogether.
If you are trying to work out whether the nurse practitioner you are seeing can prescribe for ADHD, the answer depends on which state you are in, not on the prescriber's qualifications.
What qualifies a psychiatric nurse practitioner to prescribe ADHD medication?
A psychiatric-mental health nurse practitioner holds a master's or doctoral degree in psychiatric nursing, national board certification in psychiatric-mental health, and state licensure as an advanced practice registered nurse. PMHNPs complete the same clinical training in psychopharmacology and psychiatric diagnosis as psychiatrists — the curriculum covers stimulants, non-stimulants, antidepressants, mood stabilizers and antipsychotics — and the federal DEA registration process is identical for both.
The distinction is not clinical preparation. It is legal authority, which varies by state.
Do psychiatric nurse practitioners need a DEA number to prescribe stimulants?
Yes. Any prescriber who writes prescriptions for controlled substances — including ADHD stimulants classified as Schedule II under the Controlled Substances Act — must obtain a federal DEA registration number. Under the MATE Act, every DEA-registered practitioner, nurse practitioners included, must complete at least 8 hours of one-time training on treating and managing patients with opioid or other substance use disorders, attested at the first registration or renewal on or after June 27, 2023, and both the registration and the training apply regardless of whether the prescriber practices independently or under supervision.
A PMHNP who does not hold DEA registration cannot prescribe stimulants or any other controlled substance, even in a state with full practice authority.
Which states allow psychiatric nurse practitioners to prescribe ADHD medication independently?
As of 2026, 27 states and Washington D.C. grant full practice authority to nurse practitioners, which means PMHNPs in those states can evaluate, diagnose, prescribe and manage treatment without a collaborative agreement or physician oversight. Connecticut, Massachusetts, New Hampshire, Maine and Rhode Island all have full practice authority — a PMHNP licensed in any of those states can prescribe ADHD medications independently.
Virginia, where NCNE also provides care, is classified as a restricted practice state and requires nurse practitioners to work under a practice agreement with a physician, though prescribing authority for controlled substances is still permitted within that arrangement.
Are there states where nurse practitioners cannot prescribe ADHD stimulants at all?
Yes. Texas law prohibits nurse practitioners from prescribing Schedule II controlled substances in outpatient settings, which means NPs in Texas cannot prescribe Adderall, Vyvanse, Ritalin or other stimulants for ADHD patients even with physician supervision. Georgia, Oklahoma, South Carolina and West Virginia similarly restrict or prohibit nurse practitioners from prescribing Schedule II medications.
For people located in those states, a psychiatrist or other physician is required for stimulant prescriptions.
Can a psychiatric nurse practitioner prescribe ADHD medication via telehealth?
In most cases, yes — but federal rules are in flux. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 ordinarily requires an in-person medical evaluation before a prescriber can issue a controlled substance prescription, but temporary federal extensions have allowed Schedule II stimulants to be prescribed via telehealth without an initial in-person visit. In a fourth temporary extension published on December 31, 2025, the DEA and the Department of Health and Human Services extended that flexibility through December 31, 2026, after which the in-person requirement may return unless a further extension or a final rule replaces it.
State telehealth laws also apply. A PMHNP must be licensed in the state where the patient is physically located during the visit, which is the same licensing rule that applies to psychiatrists providing telehealth care.
What ADHD medications can a psychiatric nurse practitioner prescribe?
PMHNPs prescribe the full range of ADHD medications, both stimulant and non-stimulant, in states where their scope of practice permits it:
- Schedule II stimulants — amphetamine-based medications (Adderall, Vyvanse, Dexedrine) and methylphenidate-based medications (Ritalin, Concerta, Focalin). These are the most commonly prescribed ADHD treatments and carry the tightest prescribing restrictions.
- Non-stimulant medications — atomoxetine (Strattera), viloxazine (Qelbree), and guanfacine (Intuniv), which are not controlled substances and face fewer state-level restrictions.
- Antidepressants used off-label for ADHD — bupropion (Wellbutrin) in particular, which some prescribers use when stimulants are contraindicated or have failed.
Where state law limits Schedule II prescribing, PMHNPs can still prescribe non-stimulant ADHD medications, which are effective for some patients and avoid the regulatory complexity of controlled substances.
Is care from a psychiatric nurse practitioner different from care from a psychiatrist?
Not in clinical terms. The evaluation, the questions asked, the diagnostic process and the medication management follow-up are the same whether the prescriber is an MD, DO or PMHNP. Both are trained to assess ADHD, differentiate it from conditions that can look similar, and manage stimulant treatment safely — including monitoring for misuse, diversion or cardiovascular risk.
The practical difference is access. There are fewer psychiatrists than PMHNPs in most regions, wait times for psychiatrist appointments are longer, and nurse practitioners are more likely to accept insurance. For ADHD medication management, particularly in telehealth settings, a PMHNP offers the same clinical care with meaningfully shorter wait times.
What happens at an ADHD evaluation with a psychiatric nurse practitioner?
An initial ADHD evaluation is a comprehensive visit, a 60-minute video visit at NCNE, covering current symptoms, how long they have been present, how they affect work or school, previous diagnoses and treatments, medical history, and what you have already tried. You will be asked specific questions about attention, focus, impulsivity, hyperactivity, sleep, substances and mood — ADHD symptoms overlap with anxiety, depression and sleep disorders, so the evaluation works to distinguish between them.
Not every evaluation ends with a prescription. Where symptoms are better explained by something else, or where non-medication interventions have not yet been tried, that will be part of the plan. Where medication is appropriate, you should leave understanding what was prescribed, what to expect in the first weeks, what side effects to watch for, and when you will be seen again for follow-up.
Does NCNE prescribe ADHD medication?
NCNE provides psychiatric medication management for adults aged 18 to 65, which includes evaluation and treatment of ADHD where clinically appropriate. We are licensed in Connecticut, Massachusetts, New Hampshire, Maine, Rhode Island and Virginia — five full practice authority states and one restricted practice state — and all six permit psychiatric nurse practitioners to prescribe stimulants and non-stimulant ADHD medications via telehealth.
ADHD medication management at NCNE follows the same careful, individualized approach as treatment for anxiety or depression: a thorough evaluation first, a clear explanation of what medication does and does not do, regular follow-up with measurement-based monitoring, and adjustments as needed. We do not prescribe benzodiazepines or opioid treatments, and stimulant prescriptions are managed under the DEA and state regulations that apply to all controlled substances.
Getting started
If you are seeking ADHD evaluation or medication management and are located in Connecticut, Massachusetts, New Hampshire, Maine, Rhode Island, Virginia or Kentucky, NCNE can help. The initial evaluation is where diagnosis and treatment options are worked through properly — there is no obligation to start a medication, and the visit is designed to answer your questions as much as ours. You can send a message and we will respond within two business days, or check insurance and fees first.
If you are in immediate danger, call 911. For urgent support at any hour, call or text 988 (Suicide & Crisis Lifeline). This article is general information, not medical advice. Never start, stop or change a prescribed medication without speaking to your prescriber. Federal telehealth rules for controlled substances are subject to change; verify current regulations with your provider.
Sources
- StatPearls. (2026). Practitioners and Prescriptive Authority. National Center for Biotechnology Information.
- Nurse.Org. (2026). PMHNP Scope of Practice by State: Where Can You Practice Independently?
- NurseJournal.org. (2026). Nurse Practitioner Practice Authority: A State-by-State Guide.
- Psychiatry Redefined. (2026). What States Can PMHNPs Practice Independently?
- Drug Enforcement Administration. MATE Act Q&A. https://www.deadiversion.usdoj.gov/faq/MATE_Act_faq.html
- Drug Enforcement Administration & Department of Health and Human Services. (2025, December 31). Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications. Federal Register, 90 FR 61301. https://www.federalregister.gov/documents/2025/12/31/2025-24123/fourth-temporary-extension-of-covid-19-telemedicine-flexibilities-for-prescription-of-controlled